Dear Editor, We report a case of steroid refractory human immune deficiency virus-related immune thrombocytopenic purpura (HIV-TP) successfully treated with single dose of intravenous Anti-Rh (Anti D). Although anti-retroviral treatment is the preferred first option in this situation, we treated him with steroids and, subsequently, with Anti D partly according to the patient's wishes. He showed a durable response (nearly 2 years now) to a single dose of treatment.
We propose that Anti D should be considered before antiretroviral treatment, at least in some patients.
A 25-year-old man was referred to the haematology unit for further investigation of symptomatic thrombocytopenia. He had a known history of HIV infection for 5 years but has been asymptomatic till this point. The laboratory examination showed platelet count of 30×10 9 /L with normal white cell count and haemoglobin. All other biochemical and haematological parameters were normal. The CD4 + /CD3 + count on peripheral blood was 450/µL. On further investigations, the bone marrow aspirate showed increased megakaryocytes compatible with a diagnosis of peripheral consumption as the cause for low platelet count. A provisional diagnosis of ITP was made and he was treated with steroids without any response. A dose of Anti D gave an excellent initial response to the therapy, acquiring a platelet count of over 200×10 9 /L. Subsequently, the platelet count fluctuated between 185×10 9 /L and 50×10 9 /L; but despite only having a single dose of therapy, he has been asymptomatic and did not need any further treatment. The variability of platelet count during the course of disease is illustrated on Fig. 1 .
HIV is one of the many causes of secondary ITP. Thrombocytopenia was associated with AIDS even before the discovery of HIV [1] . While a number of different mechanisms have been reported by which HIV infection could produce thrombocytopenia, the ability of effective anti-retroviral therapy to improve platelet counts demonstrates a close association between HIV replication and thrombocytopenia. Probable mechanisms of thrombocytopenia include anti-platelet glycoprotein antibodies; anti-HIV antibodies that cross-react with platelet membrane glycoproteins, platelet clearance due to immune complex disease and decreased platelet production/ineffective erythropoiesis. Thrombocytopenia is more common in patients with advanced HIV with CD4 lymphocyte count of less than 200/µL [2] . Interestingly, our patient had thrombocytopenia with normal CD4 count. HIV-TP has been shown to correlate with the degree of HIV viral load [3] and respond well to anti-retroviral treatment [4] . Hence, highly active anti-retroviral therapy (HAART) is considered as the firstIVIg or Anti D. Anti D has been identified as an effective treatment in HIV-TP, but long-term remission after single dose is very rare. Our patient showed an excellent response to a single dose of Anti D and remained asymptomatic for nearly 2 years. This case illustrates the value of Anti D in gaining long-term remission in HIV-TP, and we propose Anti-Rh (Anti D) should be considered in at least selected patients before proceeding for HAART.
